Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat EstimatesZacks Investment Research • 02/27/25
Seeking Clues to Collegium Pharmaceutical (COLL) Q4 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 02/26/25
Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025GlobeNewsWire • 02/13/25
Collegium Pharmaceutical: Strong Growth With Pain Management And ADHD ExpansionSeeking Alpha • 11/26/24
Knight Therapeutics Announces Health Canada Approval for JORNAY PM™ to Treat Attention-Deficit Hyperactivity Disorder (ADHD)GlobeNewsWire • 11/14/24
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?Zacks Investment Research • 11/13/24
Is the Options Market Predicting a Spike in Collegium Pharmaceutical (COLL) Stock?Zacks Investment Research • 11/08/24
Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag EstimatesZacks Investment Research • 11/07/24
Collegium to Participate in H.C. Wainwright 26th Annual Global Investment ConferenceGlobeNewsWire • 08/30/24
Collegium Pharmaceutical (COLL) Q2 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks Investment Research • 08/08/24
Unveiling Collegium Pharmaceutical (COLL) Q2 Outlook: Wall Street Estimates for Key MetricsZacks Investment Research • 08/07/24
Collegium Pharmaceutical (COLL) Soars 10.6%: Is Further Upside Left in the Stock?Zacks Investment Research • 07/31/24